Tri-ing to decipher trisomy AML.
cytogenetic abnormalities
myeloid neoplasms
trisomy AML
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
08 Jan 2024
08 Jan 2024
Historique:
received:
23
12
2023
accepted:
27
12
2023
medline:
9
1
2024
pubmed:
9
1
2024
entrez:
8
1
2024
Statut:
aheadofprint
Résumé
Lam et al. compared trisomy acute myeloid leukaemia (AML) patients (inclusive of single trisomy, double trisomy or tetrasomy cases) with cytogenetically normal AML to uncover distinguishing molecular and prognostic features of trisomy AML. The study contributes to our understanding of trisomy AML, but the heterogeneity of trisomy subtypes remains a barrier to its study. Commentary on: Lam et al. Distinct karyotypic and mutational landscape in trisomy AML. Br J Haematol 2024 (Online ahead of print). doi: 10.1111/bjh.19249.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 British Society for Haematology and John Wiley & Sons Ltd.
Références
Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an International Expert Panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453-474.
Papaemmanuil E, Döhner H, Campbell PJ. Genomic classification in acute myeloid leukemia. N Engl J Med. 2016;375(9):900-901.
Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 ELN recommendations from an international expert panel. Blood. 2022;140:1345-1377.
Bhatnagar B, Eisfeld AK, Kohlschmidt J, Mrózek K, Nicolet D, Papaioannou D, et al. Clinical and molecular characterization of patients with acute myeloid leukemia and sole trisomies of chromosomes 4, 8, 11, 13 or 21. Leukemia. 2020;34(2):358-368.
Lazarevic VL, Rosso A, Juliusson G, Antunovic P, Derolf ÅR, Deneberg S, et al. Incidence and prognostic significance of isolated trisomies in adult acute myeloid leukemia: a population-based study from the Swedish AML registry. Eur J Haematol. 2017;98(5):493-500.
Lam ST, Pui S, Fung CY, Saw NY, Javed A, Ip H-W, et al. Distinct karyotypic and mutational landscape in trisomy AML. Br J Hematol. 2024.
Herold T, Rothenberg-Thurley M, Grunwald VV, Janke H, Goerlich D, Sauerland MC, et al. Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia. Leukemia. 2020;34(12):3161-3172.
Shimony S, Garcia JS, Keating J, Chen EC, Luskin MR, Stahl M, et al. Molecular ontogeny in AML is both prognostic and predictive in patients treated with hypomethylating agents plus venetoclax. Blood. 2023;142(Suppl 1):977.
Döhner H, Pratz KW, DiNardo CD, Jonas BA, Pullarkat VA, Thirman MJ, et al. ELN risk stratification is not predictive of outcomes for treatment-Naïve patients with acute myeloid leukemia treated with venetoclax and azacitidine. Blood. 2022;140(Suppl 1):1441-1444.
Herold T, Metzeler KH, Vosberg S, Hartmann L, Röllig C, Stölzel F, et al. Isolated trisomy 13 defines a homogeneous AML subgroup with high frequency of mutations in spliceosome genes and poor prognosis. Blood. 2014;124(8):1304-1311.
Rainis L, Bercovich D, Strehl S, Teigler-Schlegel A, Stark B, Trka J, et al. Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21. Blood. 2003;102(3):981-986.